Scholarlink

<p>Cisplatin is a widely-used chemotherapeutic agent, but its dose-limiting ototoxicity often results in irreversible hearing loss. The pathogenesis involves oxidative stress, apoptosis, DNA damage, and inflammatory responses, yet effective preventive strategies remain limited. Here, we demonstrate that magnesium hydride (MgH<sub>2</sub>), a hydrogen-releasing compound, provides robust protection against cisplatin-induced hearing loss. Our results showed that MgH<sub>2</sub> protected auditory function and preserved cochlear hair cells <i>in vivo</i>. Furthermore, it significantly attenuated cisplatin-induced oxidative stress and apoptosis in cultured HEI-OC1 (House Ear Institute-Organ of Corti 1) cells and cochlear explants. Notably, MgH<sub>2</sub> suppressed NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated inflammatory cascades, thereby limiting downstream inflammatory damage. These findings revealed that MgH<sub>2</sub> alleviated cisplatin-induced hearing loss through integrated antioxidant, anti-inflammatory, and anti-apoptotic pathways, with NLRP3 identified as a critical regulatory molecule. Collectively, our study provides compelling evidence for MgH<sub>2</sub> as a potential therapeutic candidate for the prevention of cisplatin-induced hearing loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Potential of MgH2 in Mitigating Cisplatin-Induced Hearing Loss

  • 期刊论文

  • 发表日期：

    2025年8月11日

查看全文
  • Yibing Hu,
  • Yihuan Zhang,
  • Shufen Li,
  • Yuan Yu,
  • Jingjing Wang,
  • Zihan Lou,
  • Boya Zhang,
  • Yazhi Xing,
  • Zhengnong Chen

摘要

Cisplatin is a widely-used chemotherapeutic agent, but its dose-limiting ototoxicity often results in irreversible hearing loss. The pathogenesis involves oxidative stress, apoptosis, DNA damage, and inflammatory responses, yet effective preventive strategies remain limited. Here, we demonstrate that magnesium hydride (MgH2), a hydrogen-releasing compound, provides robust protection against cisplatin-induced hearing loss. Our results showed that MgH2 protected auditory function and preserved cochlear hair cells in vivo. Furthermore, it significantly attenuated cisplatin-induced oxidative stress and apoptosis in cultured HEI-OC1 (House Ear Institute-Organ of Corti 1) cells and cochlear explants. Notably, MgH2 suppressed NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated inflammatory cascades, thereby limiting downstream inflammatory damage. These findings revealed that MgH2 alleviated cisplatin-induced hearing loss through integrated antioxidant, anti-inflammatory, and anti-apoptotic pathways, with NLRP3 identified as a critical regulatory molecule. Collectively, our study provides compelling evidence for MgH2 as a potential therapeutic candidate for the prevention of cisplatin-induced hearing loss.